Company profile: Gradalis

1.1 - Company Overview

Gradalis

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of personalized cancer immunotherapy leveraging patients' own genetically modified tumor cells to enhance immune recognition and killing through its Vigil platform, and of clinical trials evaluating the safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewing’s sarcoma.

Products and services

Cancer Immunotherapy Manufacturing: Produces cancer-focused immunotherapy for treatment of malignancies, including patient-derived, genetically modified approaches like Vigil that aim to enhance immune recognition and killing of cancer cells
Vigil Personalized Immunotherapy Platform: Develops patient-specific immunotherapy by utilizing the patient’s own cancer cells genetically modified to strengthen immune system recognition and killing of cancer cells
Clinical Trials for Vigil: Architects indication-specific research studies involving patients to test safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewing’s sarcoma

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Gradalis

Acepodia

HQ: United States Website

Description: Provider of cancer cell therapies and platform technology, including ACC (Antibody-Cell Conjugation) to attach tumor-targeting antibodies to immune cells without genetic engineering; off-the-shelf allogeneic γδ2 T cell therapies; and ACC-γδ2 T cell candidates ACE1831 (CD20), ACE2016 (EGFR), and ACE1708 (PD-L1).

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Acepodia company profile →

Tokai Pharmaceuticals

HQ: United States Website

Description: Provider of cancer therapies, focused on developing and delivering treatments for patients living with cancer.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Tokai Pharmaceuticals company profile →

Celsee

HQ: United States Website

Description: Provider of an easy-to-use platform for cancer research and diagnosis in the emerging liquid-biopsy field, offering an instrument system and reagent kit to separate, detect, and retrieve circulating tumor cells (CTCs) from peripheral whole blood; formerly DeNovo Sciences.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Celsee company profile →

Varian

HQ: United States Website

Description: Provider of medical devices and software for treating cancer and other conditions via radiotherapy, radiosurgery, proton therapy, and brachytherapy. Offers informatics software; products such as Ethos Adaptive Radiotherapy System, IntelliBlate Microwave Ablation System, Laguna Thrombectomy System, and Varian Marketplace, plus Advanced Oncology Solutions providing clinical and professional support and workflow solutions.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Varian company profile →

AB Science

HQ: France Website

Description: Provider of pharmaceutical therapies specializing in tyrosine kinase inhibitors, including Masitinib being developed for ALS, indolent systemic mastocytosis, severe asthma, progressive MS, first-line pancreatic cancer with pain, Alzheimer’s disease, and metastatic castrate-resistant prostate cancer, and AB8939, a microtubule destabilizer being developed for acute myeloid leukemia.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full AB Science company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Gradalis

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Gradalis

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Gradalis's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Gradalis's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Gradalis

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Gradalis's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Gradalis's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Gradalis

4.2 - Public trading comparable groups for Gradalis

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Gradalis

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Gradalis

What does Gradalis do?

Gradalis is a provider of personalized cancer immunotherapy leveraging patients' own genetically modified tumor cells to enhance immune recognition and killing through its Vigil platform, and of clinical trials evaluating the safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewing’s sarcoma.

Who are Gradalis's competitors?

Gradalis's competitors and similar companies include Acepodia, Tokai Pharmaceuticals, Celsee, Varian, and AB Science.

Where is Gradalis headquartered?

Gradalis is headquartered in United States.

How many employees does Gradalis have?

Gradalis has 1,000 employees 🔒.

When was Gradalis founded?

Gradalis was founded in 2010 🔒.

What sector and industry vertical is Gradalis in?

Gradalis is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Gradalis

Who are the top strategic acquirers in Gradalis's sector and industry

Top strategic M&A buyers and acquirers in Gradalis's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Gradalis?

Top strategic M&A buyers groups and sectors for Gradalis include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Gradalis's sector and industry vertical

Which are the top PE firms investing in Gradalis's sector and industry vertical?

Top PE firms investing in Gradalis's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Gradalis's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Gradalis's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Gradalis's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Gradalis include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Gradalis's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Gradalis?

The key public trading comparables and valuation benchmarks for Gradalis include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Gradalis for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Gradalis with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Gradalis's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Gradalis with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Gradalis's' sector and industry vertical?

Access recent funding rounds and capital raises in Gradalis's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Gradalis

Start Free Trial Book a Demo